Tumor Ablation Market—Forecast till 2030

$4,950$7,250

As per the CRI analysis, the global tumor ablation market is estimated to witness a notable CAGR of 11.81% during the forecast period to surpass USD 2,459.74 million by the end of 2030.

Clear
SKU: MRFR220292 Category: Tag:

Description

Tumor Ablation Market—Forecast till 2030

Market Overview
As per the CRI analysis, the global tumor ablation market is estimated to witness a notable CAGR of 11.81% during the forecast period to surpass USD 2,459.74 million by the end of 2030. The major market participants in the market are proactively dealing with R&D for improving and propelling methods for tumor ablation.

Moreover, there are likewise a few dangers related to the radiofrequency removal method, for example, hyperesthesia, shallow skin contaminations over the infusion site, heat harm to structures contiguous to the objective nerve, hypersensitive response to the sedative used to numb the skin, and that’s only the tip of the iceberg.
The developing pervasiveness of disease is expanding the interest for compelling treatment. Unreasonable smoking and utilization of liquor and tobacco are the significant variables answerable for the rising predominance of malignant growth across the world.

Expanding commonness of disease across the globe goes about as a significant driver in the worldwide tumor ablation market from 2021-to to 2030. Nonetheless, incidental effects and entanglement related to tumor ablation thwart the development of the worldwide tumor ablation market during the gauge time frame. Rising R&D exercises in tumor ablation are supposed to set out freedom in the worldwide tumor ablation market.

Market Segmentation
The market segmentation of the global tumor ablation market is carried out in terms of technology, treatment, application, and end-user.

The application segment of the global tumor ablation market is categorized into liver cancer, lung cancer, kidney cancer, and others. The treatment type divides the market based on surgical ablation, and percutaneous ablation laparoscopic ablation. Europe is the second-biggest market for growth ablation because of the development of normalized strategies and instruments for cancer ablation therapy, developing interest in medical procedure radiotherapy and chemotherapy for early recognized growths, and expanding instances of different cancer among the mid-matured and geriatric populace, and rising utilization of undesirable and cancer-causing items.

Regional Analysis
Geographically, the global tumor ablation market spans North America, Europe, Asia-Pacific, Rest of the World.
North America contributed the largest market of 40.29% in 2020 and is anticipated to lead the market during the review period. The regional market is driven by the advances in percutaneous ablation, developing interest in radiofrequency ablation for hepatocellular carcinoma, expanding geriatric populace, and development of cancer-related issues among the populace matured 65 years or more.

Europe is the second-biggest market for growth ablation because of the development of normalized strategies and instruments for cancer ablation therapy, developing interest in medical procedure radiotherapy and chemotherapy for early recognized growths, and expanding instances of different cancer among the mid-matured and geriatric populace, and rising utilization of undesirable and cancer-causing items.

Asia-Pacific is supposed to fill essentially in the growth ablation market inferable from the rising utilization of cancer-causing items, for example, liquor and betel nut, restricted admission of leafy foods, a disclosure to indoor and open-air contamination, and ascend in openness to compound poisons across the region.

Key Competitors
The key players operating in the global tumor ablation include SonaCare Medical, LLC (US), Medtronic plc (Ireland), EDAP TMS (France), Angio Dynamics (US), HealthTronics, Inc (US), Johnson & Johnson (US), Boston Scientific Corporation (US), Misonix Inc (US), HistoSonics, Inc (US), Biotronik (Germany).

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 15

1.1.1 MARKET SYNOPSIS 15

2 MARKET INTRODUCTION 16

2.1 SCOPE OF THE STUDY 16

2.2 RESEARCH OBJECTIVE 16

2.3 LIST OF ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY 18

3.1 DATA MINING 18

3.2 SECONDARY RESEARCH 19

3.3 PRIMARY RESEARCH 20

3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 20

3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS 21

3.4 FORECASTING TECHNIQUES 21

3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22

3.5.1 BOTTOM-UP APPROACH 23

3.5.2 TOP-DOWN APPROACH 24

3.6 DATA TRIANGULATION 24

3.7 VALIDATION 24

4 MARKET DYNAMICS 26

4.1 OVERVIEW 26

4.2 DRIVERS 27

4.2.1 INCREASING PREVALENCE OF CANCER ACROSS THE GLOBE 27

4.2.2 RISING DEMAND FOR MINIMALLY INVASIVE TUMOR ABLATION TECHNIQUES 27

4.2.3 GROWING NUMBER OF PUBLIC-PRIVATE INITIATIVES AND FUNDING TO SUPPORT ONGOING RESEARCH ACTIVITIES RELATED TO TUMOR ABLATION 27

4.3 RESTRAINTS 28

4.3.1 SIDE-EFFECTS AND COMPLICATIONS ASSOCIATED WITH TUMOR ABLATION 28

4.3.2 DELAY IN APPROVAL AND UNFAVORABLE REGULATORY POLICY AND REIMBURSEMENT SCENARIO 28

4.4 OPPORTUNITY 29

4.4.1 RISING R&D ACTIVITIES 29

5 MARKET FACTOR ANALYSIS 30

5.1 VALUE CHAIN ANALYSIS 30

5.1.1 R&D 31

5.1.2 MANUFACTURING 31

5.1.3 DISTRIBUTION & SALES 31

5.1.4 POST-SALES MONITORING 31

5.2 PORTER’S FIVE FORCES ANALYSIS 32

5.2.1 THREAT OF NEW ENTRANTS 33

5.2.2 BARGAINING POWER OF SUPPLIERS 33

5.2.3 BARGAINING POWER OF BUYERS 33

5.2.4 THREAT OF SUBSTITUTES 33

5.2.5 INTENSITY OF RIVALRY 33

5.3 COVID-19 IMPACT ANALYSIS 34

5.3.1 IMPACT ON AVAILABILITY OF SURGICAL FACILITIES 34

5.3.2 IMPACT ON KEY PLAYERS 34

5.3.3 IMPACT ON CLINICAL TRIALS 35

5.3.4 IMPACT ON SUPPLY CHAIN 35

6 GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY 36

6.1 OVERVIEW 36

6.2 RADIOFREQUENCY 37

6.3 MICROWAVE 37

6.4 IRREVERSIBLE ELECTROPORATION 38

6.5 CRYOABLATION 39

6.6 OTHERS 40

7 GLOBAL TUMOR ABLATION MARKET, BY TREATMENT 41

7.1 OVERVIEW 41

7.2 SURGICAL ABLATION 42

7.3 PERCUTANEOUS ABLATION 42

7.4 LAPAROSCOPIC ABLATION 43

8 GLOBAL TUMOR ABLATION MARKET, BY APPLICATION 44

8.1 OVERVIEW 44

8.2 LUNG CANCER 45

8.3 KIDNEY CANCER 45

8.4 LIVER CANCER 46

8.5 OTHERS 47

9 GLOBAL TUMOR ABLATION MARKET, BY END USER 48

9.1 OVERVIEW 48

9.2 HOSPITAL AND CLINICS 49

9.3 SPECIALITY CENTERS 50

9.4 OTHERS 50

10 GLOBAL TUMOR ABLATION MARKET, BY REGION 51

10.1 OVERVIEW 51

10.2 NORTH AMERICA 52

10.2.1 US 55

10.2.2 CANADA 56

10.3 EUROPE 58

10.3.1 GERMANY 61

10.3.2 FRANCE 62

10.3.3 UK 63

10.3.4 ITALY 65

10.3.5 SPAIN 66

10.3.6 REST OF EUROPE 67

10.4 ASIA PACIFIC 69

10.4.1 CHINA 71

10.4.2 INDIA 72

10.4.3 JAPAN 74

10.4.4 SOUTH KOREA 75

10.4.5 AUSTRALIA 76

10.4.6 REST OF ASIA PACIFIC 78

10.5 REST OF THE WORLD 80

10.5.1 MIDDLE EAST 82

10.5.2 AFRICA 84

10.5.3 LATIN AMERICA 85

11 COMPETITIVE LANDSCAPE 87

11.1 OVERVIEW 87

11.2 COMPETITIVE BENCHMARKING 88

11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL TUMOR ABLATION MARKET 89

11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL TUMOR ABLATION MARKET 90

11.5 KEY DEVELOPMENT ANALYSIS 90

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 91

11.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 91

11.6.2 MERGER &ACQUISITION 91

11.7 FINANCIAL MATRIX 92

11.7.1 SALES (USD MILLION), 2020 92

11.7.2 R&D EXPENDITURE (USD MILLION), 2020 92

12 DRG COST OF CURATIVE TREATMENT 93

12.1 DIAGNOSIS-RELATED GROUP (DRG) 93

12.2 BIOPSY PROCEDURE REIMBURSEMENT 93

12.3 ABLATION PROCEDURE REIMBURSMENT 93

12.3.1 LIVER ABLATION PROCEDURE REIMBURSMENT 94

12.3.2 KIDNEY ABLATION PROCEDURE REIMBURSMENT 94

12.3.3 LUNG ABLATION PROCEDURE REIMBURSMENT 95

12.4 IMAGING PROCEDURE REIMBURSMENT 95

12.5 TOTAL CURATIVE TREATMENT COSTS 96

13 COMPANY PROFILES 97

13.1 SONACARE MEDICAL 97

13.1.1 COMPANY OVERVIEW 97

13.1.2 FINANCIAL OVERVIEW 97

13.1.3 PRODUCTS/SERVICES OFFERED 97

13.1.4 KEY DEVELOPMENTS 97

13.1.5 SWOT ANALYSIS 98

13.1.6 KEY STRATEGIES 98

13.2 MEDTRONIC PLC 99

13.2.1 COMPANY OVERVIEW 99

13.2.2 FINANCIAL OVERVIEW 99

13.2.3 PRODUCTS/SERVICES OFFERED 100

13.2.4 KEY DEVELOPMENTS 100

13.2.5 SWOT ANALYSIS 100

13.2.6 KEY STRATEGIES 101

13.3 EDAP TMS 102

13.3.1 COMPANY OVERVIEW 102

13.3.2 FINANCIAL OVERVIEW 102

13.3.3 PRODUCTS/SERVICES OFFERED 103

13.3.4 KEY DEVELOPMENTS 103

13.3.5 SWOT ANALYSIS 103

13.3.6 KEY STRATEGIES 103

13.4 ANGIODYNAMICS 104

13.4.1 COMPANY OVERVIEW 104

13.4.2 FINANCIAL OVERVIEW 104

13.4.3 PRODUCTS/SERVICES OFFERED 105

13.4.4 KEY DEVELOPMENTS 105

13.4.5 SWOT ANALYSIS 105

13.4.6 KEY STRATEGIES 105

13.5 HEALTHTRONICS, INC. 106

13.5.1 COMPANY OVERVIEW 106

13.5.2 FINANCIAL OVERVIEW 106

13.5.3 PRODUCTS/SERVICES OFFERED 106

13.5.4 KEY DEVELOPMENTS 106

13.5.5 SWOT ANALYSIS 107

13.5.6 KEY STRATEGIES 107

13.6 JOHNSON & JOHNSON 108

13.6.1 COMPANY OVERVIEW 108

13.6.2 FINANCIAL OVERVIEW 108

13.6.3 PRODUCTS/SERVICES OFFERED 109

13.6.4 KEY DEVELOPMENTS 109

13.6.5 SWOT ANALYSIS 109

13.6.6 KEY STRATEGIES 109

13.7 BOSTON SCIENTIFIC CORPORATION 110

13.7.1 COMPANY OVERVIEW 110

13.7.2 FINANCIAL OVERVIEW 110

13.7.3 PRODUCTS/SERVICES OFFERED 111

13.7.4 KEY DEVELOPMENTS 111

13.7.5 SWOT ANALYSIS 111

13.7.6 KEY STRATEGIES 112

13.8 MISONIX, INC. 113

13.8.1 COMPANY OVERVIEW 113

13.8.2 FINANCIAL OVERVIEW 113

13.8.3 PRODUCTS/SERVICES OFFERED 114

13.8.4 KEY DEVELOPMENTS 114

13.8.5 SWOT ANALYSIS 114

13.8.6 KEY STRATEGIES 115

13.9 HISTOSONICS, INC. 116

13.9.1 COMPANY OVERVIEW 116

13.9.2 FINANCIAL OVERVIEW 116

13.9.3 PRODUCTS/SERVICES OFFERED 116

13.9.4 KEY DEVELOPMENTS 116

13.9.5 SWOT ANALYSIS 117

13.9.6 KEY STRATEGIES 117

13.10 BIOTRONIK 118

13.10.1 COMPANY OVERVIEW 118

13.10.2 FINANCIAL OVERVIEW 118

13.10.3 PRODUCTS/SERVICES OFFERED 118

13.10.4 KEY DEVELOPMENTS 118

13.10.5 SWOT ANALYSIS 119

13.10.6 KEY STRATEGIES 119

14 APPENDIX 120

14.1 REFERENCES 120

14.2 RELATED REPORTS 120

Companies Mentioned

SonaCare Medical, LLC (US), Medtronic plc (Ireland), EDAP TMS (France), Angio Dynamics (US), HealthTronics, Inc (US), Johnson & Johnson (US), Boston Scientific Corporation (US), Misonix Inc (US), HistoSonics, Inc (US), Biotronik (Germany)

Reviews

There are no reviews yet.

Be the first to review “Tumor Ablation Market—Forecast till 2030”